ACIU (AC Immune) Stock Based Compensation : $5.86 Mil (TTM As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is AC Immune Stock Based Compensation?

AC Immune's Stock Based Compensation for the three months ended in Mar. 2025 was $1.76 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 was $5.86 Mil.

AC Immune Stock Based Compensation Historical Data

The historical data trend for AC Immune's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AC Immune Stock Based Compensation Chart

AC Immune Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Stock Based Compensation

Get a 7-Day Free Trial

4.60

4.48

3.57

5.05

6.14

AC Immune Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Stock Based Compensation	Get a 7-Day Free Trial															2.12	1.56	1.45	1.09	1.76

AC Immune Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.86 Mil.

AC Immune Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of AC Immune's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

AC Immune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AC Immune SA (NAS:ACIU) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

IMR:Germany IMR:Germany

Address

EPFL Innovation Park, Building B, Lausanne, CHE, 1015

Website

https://www.acimmune.com

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.